{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:13:56Z","timestamp":1789146836097,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lungcan.2026.109586","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:09:27Z","timestamp":1787238567000},"page":"109586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States"],"prefix":"10.1016","volume":"220","author":[{"given":"Jhanelle E.","family":"Gray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-5698","authenticated-orcid":false,"given":"Kelli","family":"Thoele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-5182","authenticated-orcid":false,"given":"Madeline","family":"Richey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Boualam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Schwed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Brechtelsbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-0087","authenticated-orcid":false,"given":"Qinli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin M.","family":"Sheffield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lungcan.2026.109586_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071410","article-title":"Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort","volume":"16","author":"Bruno","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109586_b0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17953","article-title":"Clinical Outcomes of Perioperative Immunotherapy in Resectable Non-Small Cell Lung Cancer","volume":"8","author":"Desai","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109586_b0015","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2023.07.006","article-title":"Neoadjuvant Targeted Therapy in Resectable NSCLC: current and Future Perspectives","volume":"18","author":"Lee","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109586_b0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12032-022-01790-0","article-title":"Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence","volume":"40","author":"Bowes","year":"2022","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109586_b0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.athoracsur.2024.09.041","article-title":"The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of locally Advanced Non-small Cell Lung Cancer","volume":"119","author":"Kim","year":"2025","journal-title":"Ann. Thorac. Surg."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109586_b0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1200\/JCO.19.02748","article-title":"Lung Cancer Surveillance after Definitive Curative-intent Therapy: ASCO Guideline","volume":"38","author":"Schneider","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109586_b0035","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/JTO.0000000000000483","article-title":"Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC","volume":"10","author":"van den Berg","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109586_b0040","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241308466","article-title":"Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations","volume":"16","author":"Ghazali","year":"2024","journal-title":"Ther Adv Med Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109586_b0045","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.3390\/jcm14124127","article-title":"Systemic Therapy for Operable NSCLC: a Review of the Literature and Discussion of Future Directions","volume":"14","author":"Mirsky","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lungcan.2026.109586_b0050","article-title":"New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe","volume":"38","author":"Houda","year":"2024","journal-title":"Lancet Reg Health Eur."},{"key":"10.1016\/j.lungcan.2026.109586_b0055","unstructured":"Bristol-Myers Squibb Company. OPDIVO(R) (nivolumab) Prescribing Information. FDA; 2025."},{"key":"10.1016\/j.lungcan.2026.109586_b0060","unstructured":"Merck & Co. KEYTRUDA(R) (pembrolizumab) Prescribing Information. FDA; 2025."},{"key":"10.1016\/j.lungcan.2026.109586_b0065","unstructured":"Genentech I. TECENTRIQ (atezolizumab) Prescribing Information. FDA; 2025."},{"key":"10.1016\/j.lungcan.2026.109586_b0070","unstructured":"AstraZeneca. IMFINZI\u00ae (durvalumab) Prescribing Information. FDA; 2025."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109586_b0075","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-472804","article-title":"Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: current strategies and Unanswered questions","volume":"45","author":"Voruganti","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"26","key":"10.1016\/j.lungcan.2026.109586_b0080","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer","volume":"43","author":"He","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109586_b0085","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/JCO.2025.43.16_suppl.8015","article-title":"Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316)","volume":"43","author":"Leonetti","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109586_b0090","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1016\/j.jtho.2025.09.1025","article-title":"P3.18.09 SUNRAY-02: a phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-mutant NSCLC after Definitive Therapy","volume":"20","author":"Nadal","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109586_b0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109586_b0100","unstructured":"FlatironHealth. Database Characterization Guide 2025 [updated Published March 18, 2025. Available from: https:\/\/flatiron.com\/database-characterization."},{"issue":"26","key":"10.1016\/j.lungcan.2026.109586_b0105","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO-25-01020","article-title":"Neoadjuvant Osimertinib: a step Ahead or just a step?","volume":"43","author":"Ramalingam","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109586_b0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17962","article-title":"Immunotherapy for Resectable Non-Small Cell Lung Cancer-not if, but when","volume":"8","author":"Reed-Guy","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.lungcan.2026.109586_b0115","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/jnci\/djaf090","article-title":"Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis","volume":"117","author":"Nuccio","year":"2025","journal-title":"J. Natl Cancer Inst."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109586_b0120","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations from the International Association for the Study of Lung Cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109586_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108635","article-title":"ETOP 25-23 ADOPT-lung: an international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC","volume":"206","author":"Schmid","year":"2025","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109586_b0130","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cllc.2022.12.005","article-title":"Treatment patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: an Analysis of the SEER-Medicare Data","volume":"24","author":"West","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109586_b0135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40801-025-00487-w","article-title":"Real-World Clinical Characteristics, Treatment patterns, and Clinical Outcomes in US patients with Stage I-III Resected NSCLC without known EGFR Mutations: the RESECT Study","volume":"12","author":"Gray","year":"2025","journal-title":"Drugs Real World Outcomes."},{"key":"10.1016\/j.lungcan.2026.109586_b0140","doi-asserted-by":"crossref","unstructured":"Dafni U, Tsourti Z, Vervita A, Zygoura P, Peters S. Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients with Resectable NSCLC: Still an Open Question. Comments on Marinelli et al. J Thorac Oncol. 2025;20:285-295. J Thorac Oncol. 2025;20(9):1336-41.","DOI":"10.1016\/j.jtho.2025.05.007"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109586_b0145","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.014","article-title":"PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816","volume":"19","author":"Forde","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109586_b0150","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (lung ART, IFCT 0503): an open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2021","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109586_b0155","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jtho.2022.11.027","article-title":"Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma","volume":"18","author":"Muthusamy","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109586_b0160","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2025.43.16_suppl.8001","article-title":"Neoadjuvant (neoadj) osimertinib (osi) \u00b1 chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA","volume":"43","author":"Chaft","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109586_b0165","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109586_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061853","article-title":"Replication of Real-World evidence in Oncology using Electronic Health Record Data Extracted by Machine Learning","volume":"15","author":"Benedum","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109586_b0175","article-title":"Raising the Bar for Real-World Data in Oncology: Approaches to Quality across Multiple Dimensions","volume":"8","author":"Castellanos","year":"2024","journal-title":"JCO Clin Cancer Inform."},{"issue":"13","key":"10.1016\/j.lungcan.2026.109586_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133063","article-title":"Considerations for the use of Machine Learning Extracted Real-World Data to support evidence Generation: a Research-Centric Evaluation Framework","volume":"14","author":"Estevez","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:52:33Z","timestamp":1789145553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S0169500226006471"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109586","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109586"}}